Patient-specific genomic measurable residual disease markers for monitoring acute myeloid leukaemia and myeloid malignancy.
Custom genetic tests for individual leukemia patients enable doctors to track disease burden more sensitively than standard methods, helping predict treatment response.
This multi-center Australian study developed patient-specific PCR-MRD assays using genomic sequencing for AML and myeloid malignancies, addressing the key limitation that existing MRD methods (flow cytometry, RNA PCR) cannot be universally applied. Assays were successfully developed for nearly all patients and prospectively applied to 40 patients, with serial MRD correlating with clinical outcomes and showing higher sensitivity than ALL MRD.
What the study was
- Study design
- Prospective cohort study with assay development component; patient-specific PCR-MRD assays developed from NGS/WGS data and applied prospectively across multiple Australian pediatric and adult centers
- Population
- Pediatric and adult myeloid malignancy patients across multiple Australian centers (prospective MRD monitoring cohort n=40)
- Sample size
- 97.6% assay development rate; 40 patients in prospective MRD monitoring cohort
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- British Journal of Haematology
Why it surfaced
Directly addresses a clinical gap (AML MRD cannot be applied universally with current methods); prospective multi-center data with 97.6% assay success rate and outcome correlation—advances toward standard-of-care MRD monitoring in AML.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.